 |
| |
REPORT SCOPE:
The Pharmaceutical Market report is part of the new industrial series from OCO Consulting.
The report aims to provide an accurate and concise overview of the key trends in the pharmaceutical market during the last five years and to highlight the major factors that are impacting on its performance. Pharmaceutical manufacturing in Ireland is one of the most successful foreign direct investment (FDI) activities of the last four decades – attracting the majority of global players over the years.
Generating a positive trade balance of £7.5 billion in 2003, Ireland’s pharmaceutical manufacturing volume is amongst the world’s leading countries – the actual export figure of €37 billion is more than 40% of all Irish exports.
This report looks at two levels – the global industry with the key drivers including R&D investment, drug pipelines, patent expiry and M&A activity.
On a domestic scale, the local market is driven by demographics, healthcare delivery and the two national economies.
Trade data and company profiles for the key Irish players on the supply channels are provided, with profiles of the multinational investment sites also included. The RoI and NI domestic supply chains are also supplied in detail.
The trends and opportunities in each of the key segments of the pharmaceutical industry are assessed in detail.
Forecasts for the pharmaceutical industry show global market growth of 6-7%, with emerging markets generating the double-digit growth that used to be the industry norm – markets like China and Eastern Europe will lead. In Ireland, spending will continue to rise in line with GDP, with a real increase in generic products.
PUBLICATION DATE:
The IRELAND PHARMACEUTICAL PRODUCTS MARKET RESEARCH REPORT was last updated:
February 2006
PRICES:
A single report is priced at £695 ($1325)
Reports are also available by individual chapters, please use the MBD ecommerce link to view prices for these.
OPTIONS:
CONTENT:
Table of Contents
Introduction
Figure 1: World Trade in Pharmaceuticals, 2003
Definition
Geographical, national and regional definitions
Conversion factors
Exchange rates
Abbreviations
Executive Summary
Market size
Market drivers
Global driver
1. R&D focu
2. Licensing and M&A
3. Patent expiry
4. Regulatory activity & safety
Local drivers
1. Healthcare spending
2. Local populations & health
3. Government strategy
Supply sector
Opportunities, threats & forecast
Outlook summary
Market Driver
Global driver
Figure 2: Number of New Active Substances (NASs) Launched Globally Over 5-20 Year Timefram
R&D investment & drug discover
Figure 3: Biotech NAS Launches as % of Total (Global), 1995-2004
Licensing, mergers & acquisitions (M&A)
Figure 5: development Stage at First Licensing
Regulatory environment
Local drivers
Healthcare systems/ healthcare spending
NHS in Northern Ireland
OTC sales & self treatment
Population health
State/Government incentives for manufacturing & investment
Figure 6: Manufacturing Expansions, RoI,1999 - 2005
Figure 7: Manufacturing Greenfield Sites, RoI, 1999-2005
Government interventions on drug pricing
Market Size & Segmentation
Global market
Figure 8: Sales of Key Therapeutic Sectors $ (bn) in Major Markets, 2002-2005
Snapshots
Figure 9: Global Top 10 Markets ($ bn), October 2005
Figure 10: Global Top 10 Prescription Products, October 2005
Figure 11: Top 10 Therapeutic Categories, October 2005
Figure 12: Top 10 Global Pharma Manufacturers, October 2005
Irish market (RoI & NI)
Local market: RoI
Figure 13: Global Top 20 Pharma Companies (By Worldwide Sales Value) by Presence of Irish Site, Sales, Growth & Market Share, 2003
Local market: NI
Supply Structure
Republic of Ireland
Multinational pharmaceutical manufacturing sites:
Abbott
Altana
Astellas
Bayer
Bayer Diagnostics Europe Limited
Bristol Myers Squibb (BMS)
E Lilly & Co
GlaxoSmithKline (GSK)
Henkel
IVAX
Johnson & Johnson
Leo
Merck Sharpe & Dohme (MSD)
Novartis
Organon
Pfizer
Roche
Schering Plough
Takeda
Wyeth
Indigenous pharmaceutical manufacturing
Antigen (now Miza – owned by CCL of Canada)
Athlone Labs (Kent Pharma)
Clonmel (Stada)
Elan Corp
Franklin Pharmaceuticals
Gerard (Generics UK/Merck)
Newport Pharmaceuticals (Irish)
Pinewood (private Irish)
Rowa (owned by Novartis)
Aerogen
Alltracel Pharmaceutical
Honeywell
International biotech sites
Centocor – Cork
Genzyme Ireland - Waterford
Trinity Biotech
Wyeth
Indigenous biotech
Bioclin Research Labs
Eirx
Genable
IdentiGEN
Luxcel Biosciences
NeuroCure
Opsona
Proxy Biomedical Ltd – Galway
Tridelta
Major centres
Conway Institute (Biomolecular and Biomedical Research)
Cork
Dublin Molecular Medicine Center (DMMC)
Galway
National Institute – DCU
NovaUCD
Trinity College, Dublin
Domestic supply chain
Sub supply speciality sectors
Laboratory support & supply
Precision engineering
Clinical research organisations
Technology
Packaging
Northern Ireland
Multinational pharmaceutical sites
Baxter Healthcare
Galen
Kiel Laboratories
Norbrook
Randox
NI Biotech
R&D University partnerships & incubator
Bioscience and Technology Institute
University of Ulster at Coleraine
Sub supply
Clinical Research Organisations (CRO)
Packaging
Lab support & supplies
Opportunities & Threats
Forecast
RoI/NI local market forecast
Figure 14: Healthcare Spending as % of GDP, 2002-2008
Global
Cost saving strategies
Innovative pricing strategies
How will these outlook factors affect the Irish market?
Appendix: Research Methodology
|
List of Tables
|
|
|
|
